Category:
Prophylactic Biological Products
CAS NO:
1223403-58-4
Standard:
In-house Standards,

LOXO-101 is a potent, ATP competitive TRK inhibitor with IC50s in low nanomolar range for inhibition of all TRK family members in binding and cellular assays, with 100x selectivity over other kinases, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases. This is developed by Loxo Oncology.
Indication: Oncology drug
All the products under the patent are only for R&D use.
Patent from Loxo Oncology, expiry date(The U.S):Oct.21,2029.